PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial
Official title:
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
The main objective is the evaluation of the prognostic value of ctDNA (circulating tumor DNA) as a marker of surgical futility in patients with operable PDAC.
In the era of personalized medicine and treatments guided by tumor biology, no specific tumor marker has real prognostic value. This is the reason why the search for a specific marker through a noninvasive blood test that can give indications on the usefulness of the resectability of pancreatic adenocarcinoma would be very valuable. Our project proposes the evaluation of ctDNA during various treatment courses of patients with PDAC in order to evaluate its efficacy as a prognostic and predictive marker of response to treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06122896 -
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
|
Early Phase 1 | |
| Recruiting |
NCT05262855 -
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04700488 -
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
|
N/A | |
| Not yet recruiting |
NCT05947825 -
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
|
Phase 2 | |
| Recruiting |
NCT06151223 -
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
|
||
| Recruiting |
NCT05845801 -
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
|
||
| Recruiting |
NCT05669287 -
Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics
|
N/A | |
| Recruiting |
NCT05727020 -
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
|
||
| Recruiting |
NCT05218889 -
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05132244 -
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT04365049 -
Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma
|